Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Lymphoid 2Dermatologic 2Sarcoma 1Plasma cell 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Melanoma 2Skin Neoplasms 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × urelumab × Dermatologic × Clear all
NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT00612664 2015-10-12

Phase II, 2nd Line Melanoma - RAND Monotherapy

Bristol-Myers Squibb

Phase 2 Completed
158 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡